Takeda Pharmaceutical Limited's Suppliers recorded an increase in sales by 28.19 % year on year in Q4 2025, from the previous quarter, sales fell by -42.59 %, while their net margin rose to 377.81 % year on year, Takeda Pharmaceutical Limited's Suppliers improved sequentially profit margin to -42.59 %,
Takeda Pharmaceutical Limited's Suppliers recorded an increase in sales by 28.19 % year on year in Q4 2025, from the previous quarter, sales fell by -42.59 %, while their net margin rose to 377.81 % year on year, Takeda Pharmaceutical Limited's Suppliers improved sequentially profit margin to 377.81 %,
Takeda Pharmaceutical Limited's Comment on Supply Chain
The company sources raw materials and supplies globally, producing some active ingredients internally while obtaining others from third-party suppliers. It relies on plasma donations from healthy individuals, operating plasma donation centers in the United States, Austria, Hungary, and Czechia, and maintains partnerships with additional plasma suppliers. To manage supply chain risks, the company diversifies its sources, maintains strategic inventory levels, and invests in internal manufacturing capacity and dual sourcing. Its manufacturing operations are regulated by authorities including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, and National Medical Products Administration (NMPA) of China. The company operates a global manufacturing network and utilizes over 100 contract manufacturers for various production stages, often employing dual sourcing with internal sites or mitigating single-source risks through additional inventory.
Takeda Pharmaceutical Limited's Comment on Supply Chain
The company sources raw materials and supplies globally, producing some active ingredients internally while obtaining others from third-party suppliers. It relies on plasma donations from healthy individuals, operating plasma donation centers in the United States, Austria, Hungary, and Czechia, and maintains partnerships with additional plasma suppliers. To manage supply chain risks, the company diversifies its sources, maintains strategic inventory levels, and invests in internal manufacturing capacity and dual sourcing. Its manufacturing operations are regulated by authorities including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, and National Medical Products Administration (NMPA) of China. The company operates a global manufacturing network and utilizes over 100 contract manufacturers for various production stages, often employing dual sourcing with internal sites or mitigating single-source risks through additional inventory.
TAK's Suppliers Net Income grew by
TAK's Suppliers Net margin grew in Q4 to
377.81 %
TAK's Suppliers Net Income grew by
TAK's Suppliers Net margin grew in Q4 to 377.81 %
Takeda Pharmaceutical Limited's Suppliers Sales Growth
in Q4 2025 by Industry
Sources:
Takeda Pharmaceutical Company Limited's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Takeda Pharmaceutical Company Limited’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
28.19 %